Literature DB >> 34024019

Up-regulation of pro-angiogenic molecules and events does not relate with an angiogenic switch in metastatic osteosarcoma cells but to cell survival features.

Luciana M Gutiérrez1, Matías Valenzuela Alvarez1, Yuanzheng Yang2, Fiorella Spinelli3, María José Cantero4, Laura Alaniz3, Mariana G García4, Eugenie S Kleinerman2, Alejandro Correa5, Marcela F Bolontrade6.   

Abstract

Osteosarcoma (OS) is the most frequent malignant bone tumor, affecting predominantly children. Metastases represent a major clinical challenge and an estimated 80% would present undetectable micrometastases at diagnosis. The identification of metastatic traits and molecules would impact in micrometastasis management. We demonstrated that OS LM7 metastatic cells secretome was able to induce microvascular endothelium cell rearrangements, an angiogenic-related trait. A proteomic analysis indicated a gain in angiogenic-related pathways in these cells, as compared to their parental-non-metastatic OS SAOS2 cells counterpart. Further, factors with proangiogenic functions like VEGF and PDGF were upregulated in LM7 cells. However, no differential angiogenic response was induced by LM7 cells in vivo. Regulation of the Fas-FasL axis is key for OS cells to colonize the lungs in this model. Analysis of the proteomic data with emphasis in apoptosis pathways and related processes revealed that the percentage of genes associated with those, presented similar levels in SAOS2 and LM7 cells. Further, the balance of expression levels of proteins with pro- and antiapoptotic functions in both cell types was subtle. Interestingly and of relevance to the model, Fas associated Factor 1 (FAF1), which participates in Fas signaling, was present in LM7 cells and was not detected in SAOS2 cells. The subtle differences in apoptosis-related events and molecules, together with the reported cell-survival functions of the identified angiogenic factors and the increased survival features that we observed in LM7 cells, suggest that the gain in angiogenesis-related pathways in metastatic OS cells would relate to a prosurvival switch rather to an angiogenic switch as an advantage feature to colonize the lungs. OS metastatic cells also displayed higher adhesion towards microvascular endothelium cells suggesting an advantage for tissue colonization. A gain in angiogenesis pathways and molecules does not result in major angiogenic potential. Together, our results suggest that metastatic OS cells would elicit signaling associated to a prosurvival phenotype, allowing homing into the hostile site for metastasis. During the gain of metastatic traits process, cell populations displaying higher adhesive ability to microvascular endothelium, negative regulation of the Fas-FasL axis in the lung parenchyma and a prosurvival switch, would be selected. This opens a new scenario where antiangiogenic treatments would affect cell survival rather than angiogenesis, and provides a molecular panel of expression that may help in distinguishing OS cells with different metastatic potential.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Angiogenesis; Apoptosis; Metastasis; Osteosarcoma; Prosurvival phenotype

Mesh:

Substances:

Year:  2021        PMID: 34024019     DOI: 10.1007/s10495-021-01677-x

Source DB:  PubMed          Journal:  Apoptosis        ISSN: 1360-8185            Impact factor:   4.677


  64 in total

Review 1.  Mesenchymal stroma: Role in osteosarcoma progression.

Authors:  Margherita Cortini; Sofia Avnet; Nicola Baldini
Journal:  Cancer Lett       Date:  2017-07-31       Impact factor: 8.679

2.  Human mesenchymal stem cells (hMSCs) target osteosarcoma and promote its growth and pulmonary metastasis.

Authors:  Wen-ting Xu; Zhen-yu Bian; Qi-ming Fan; Gang Li; Ting-ting Tang
Journal:  Cancer Lett       Date:  2009-04-01       Impact factor: 8.679

Review 3.  Bone microenvironment signals in osteosarcoma development.

Authors:  Arantzazu Alfranca; Lucia Martinez-Cruzado; Juan Tornin; Ander Abarrategi; Teresa Amaral; Enrique de Alava; Pablo Menendez; Javier Garcia-Castro; Rene Rodriguez
Journal:  Cell Mol Life Sci       Date:  2015-05-03       Impact factor: 9.261

4.  Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols.

Authors:  Stefan S Bielack; Beate Kempf-Bielack; Günter Delling; G Ulrich Exner; Silke Flege; Knut Helmke; Rainer Kotz; Mechthild Salzer-Kuntschik; Matthias Werner; Winfried Winkelmann; Andreas Zoubek; Heribert Jürgens; Kurt Winkler
Journal:  J Clin Oncol       Date:  2002-02-01       Impact factor: 44.544

Review 5.  Intravascular Survival and Extravasation of Tumor Cells.

Authors:  Boris Strilic; Stefan Offermanns
Journal:  Cancer Cell       Date:  2017-09-11       Impact factor: 31.743

6.  Increased Fas expression reduces the metastatic potential of human osteosarcoma cells.

Authors:  Elizabeth A Lafleur; Nadezhda V Koshkina; John Stewart; Shu-Fang Jia; Laura L Worth; Xiaoping Duan; Eugenie S Kleinerman
Journal:  Clin Cancer Res       Date:  2004-12-01       Impact factor: 12.531

Review 7.  Emerging Biological Principles of Metastasis.

Authors:  Arthur W Lambert; Diwakar R Pattabiraman; Robert A Weinberg
Journal:  Cell       Date:  2017-02-09       Impact factor: 41.582

8.  The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited.

Authors:  Isaiah J Fidler
Journal:  Nat Rev Cancer       Date:  2003-06       Impact factor: 60.716

9.  miR-20a Regulates FAS Expression in Osteosarcoma Cells by Modulating FAS Promoter Activity and Can be Therapeutically Targeted to Inhibit Lung Metastases.

Authors:  Yuanzheng Yang; Gangxiong Huang; Zhichao Zhou; Jason G Fewell; Eugenie S Kleinerman
Journal:  Mol Cancer Ther       Date:  2017-10-27       Impact factor: 6.261

Review 10.  Dissemination and growth of cancer cells in metastatic sites.

Authors:  Ann F Chambers; Alan C Groom; Ian C MacDonald
Journal:  Nat Rev Cancer       Date:  2002-08       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.